Larimar Therapeutics (LRMR) Competitors $4.26 +0.54 (+14.52%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$4.27 +0.01 (+0.23%) As of 08/14/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LRMR vs. PAHC, NTLA, AMPH, XERS, COLL, SNDX, PHVS, VERV, LENZ, and PRAXShould you be buying Larimar Therapeutics stock or one of its competitors? The main competitors of Larimar Therapeutics include Phibro Animal Health (PAHC), Intellia Therapeutics (NTLA), Amphastar Pharmaceuticals (AMPH), Xeris Biopharma (XERS), Collegium Pharmaceutical (COLL), Syndax Pharmaceuticals (SNDX), Pharvaris (PHVS), Verve Therapeutics (VERV), LENZ Therapeutics (LENZ), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry. Larimar Therapeutics vs. Its Competitors Phibro Animal Health Intellia Therapeutics Amphastar Pharmaceuticals Xeris Biopharma Collegium Pharmaceutical Syndax Pharmaceuticals Pharvaris Verve Therapeutics LENZ Therapeutics Praxis Precision Medicines Larimar Therapeutics (NASDAQ:LRMR) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment. Is LRMR or PAHC more profitable? Phibro Animal Health has a net margin of 2.68% compared to Larimar Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 30.51% beat Larimar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Larimar TherapeuticsN/A -52.48% -46.08% Phibro Animal Health 2.68%30.51%6.89% Does the media prefer LRMR or PAHC? In the previous week, Phibro Animal Health had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 9 mentions for Phibro Animal Health and 8 mentions for Larimar Therapeutics. Phibro Animal Health's average media sentiment score of 0.93 beat Larimar Therapeutics' score of 0.71 indicating that Phibro Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phibro Animal Health 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in LRMR or PAHC? 91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are owned by institutional investors. 4.5% of Larimar Therapeutics shares are owned by insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate LRMR or PAHC? Larimar Therapeutics presently has a consensus price target of $18.50, indicating a potential upside of 334.27%. Phibro Animal Health has a consensus price target of $24.40, indicating a potential downside of 20.18%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Larimar Therapeutics is more favorable than Phibro Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Phibro Animal Health 2 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.83 Which has more risk & volatility, LRMR or PAHC? Larimar Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Which has stronger earnings & valuation, LRMR or PAHC? Phibro Animal Health has higher revenue and earnings than Larimar Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLarimar TherapeuticsN/AN/A-$80.60M-$1.49-2.86Phibro Animal Health$1.02B1.22$2.42M$0.7839.19 SummaryPhibro Animal Health beats Larimar Therapeutics on 11 of the 16 factors compared between the two stocks. Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LRMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LRMR vs. The Competition Export to ExcelMetricLarimar TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$307.93M$2.48B$5.61B$9.84BDividend YieldN/A1.76%4.61%4.07%P/E Ratio-2.8622.0530.2925.74Price / SalesN/A742.42463.41115.83Price / CashN/A184.4138.2159.48Price / Book1.584.838.826.15Net Income-$80.60M$31.61M$3.25B$265.06M7 Day Performance18.99%4.55%3.70%2.60%1 Month Performance34.81%5.69%5.84%2.83%1 Year Performance-45.31%12.71%29.92%25.58% Larimar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LRMRLarimar Therapeutics2.7057 of 5 stars$4.26+14.5%$18.50+334.3%-43.7%$307.93MN/A-2.8630News CoverageEarnings ReportUpcoming EarningsPAHCPhibro Animal Health3.7022 of 5 stars$28.54+1.6%$24.40-14.5%+75.8%$1.14B$1.02B36.591,940Gap DownNTLAIntellia Therapeutics4.5154 of 5 stars$10.74-0.5%$30.68+185.7%-49.3%$1.12B$57.88M-2.29600Analyst ForecastAnalyst RevisionGap UpAMPHAmphastar Pharmaceuticals3.1988 of 5 stars$27.36+14.9%$30.00+9.6%-28.8%$1.11B$731.97M10.252,028Analyst UpgradeHigh Trading VolumeXERSXeris Biopharma3.4033 of 5 stars$7.20+5.3%$6.25-13.2%+186.3%$1.10B$203.07M-34.28290News CoverageAnalyst UpgradeInsider TradeAnalyst RevisionCOLLCollegium Pharmaceutical2.7537 of 5 stars$36.14+3.5%$42.33+17.1%+8.3%$1.10B$631.45M34.75210Insider TradeGap DownSNDXSyndax Pharmaceuticals4.0573 of 5 stars$12.51+0.2%$36.91+195.0%-24.8%$1.08B$23.68M-3.22110Options VolumePHVSPharvaris2.3937 of 5 stars$20.84+3.6%$36.20+73.7%+36.0%$1.05BN/A-6.9230News CoverageEarnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionVERVVerve Therapeutics2.9506 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110LENZLENZ Therapeutics1.1227 of 5 stars$38.77+11.8%$49.60+27.9%+74.1%$989.15MN/A-20.41110High Trading VolumePRAXPraxis Precision Medicines1.8554 of 5 stars$44.95-2.2%$95.22+111.8%-6.9%$966.84M$8.55M-3.66110 Related Companies and Tools Related Companies Phibro Animal Health Alternatives Intellia Therapeutics Alternatives Amphastar Pharmaceuticals Alternatives Xeris Biopharma Alternatives Collegium Pharmaceutical Alternatives Syndax Pharmaceuticals Alternatives Pharvaris Alternatives Verve Therapeutics Alternatives LENZ Therapeutics Alternatives Praxis Precision Medicines Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LRMR) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access